Skip to search formSkip to main contentSkip to account menu

Canertinib

Known as: 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, N-[-4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide, N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

CI-1033

Broader (1)

Morpholines
Receptor Tyrosine Kinase Inhibitioncanertinib dihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Engineered human pluripotent stem cell derived cardiomyocyte platforms to detect cardiovascular safety liabilities
The development and screening of new chemical entities is often a lengthy and costly process, which relies heavily on the use of… 
2013
2013
Der Einsatz von Tyrosinkinase-Inhibitoren bei aktivierenden EGFR-Mutationen in der Erstlinientherapie beim fortgeschrittenen nicht-kleinzelligen Lungen-karzinom ( NSCLC ) – aktueller Stand und…
Trotz großer Fortschritte in Forschung und Therapie in den letzten Jahren sind Lungenkarzinome nach wie vor die häufigste… 
2013
2013
Canertinib preparation method
The invention discloses a Canertinib (I) preparation method which comprises the following steps: performing etherification… 
2012
2012
Canertinib-induced leukemia cell death signaling : effects of a pan-ERBB inhibitor
Acute myelogenous leukemia (AML) is the most common acute leukemia affecting adults, the second most frequent leukemia in… 
2012
2012
Canertinib-induced leukemia cell death signaling
2009
2009
Studies on the effect of ErbB tyrosine kinase inhibitors on malignant melanoma growth and survival in vitro
The ErbB receptor family has been suggested to constitute a therapeutic target for tumor-specific treatment of malignant melanoma…